March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Choroidal Thickness Measurements During CSCR Treatment
Author Affiliations & Notes
  • Caroline Brandl
    Department of Ophthalmology, Regensburg University Hospital, Regensburg, Germany
  • Horst Helbig
    Department of Ophthalmology, Regensburg University Hospital, Regensburg, Germany
  • Maria A. Gamulescu
    Department of Ophthalmology, Regensburg University Hospital, Regensburg, Germany
  • Footnotes
    Commercial Relationships  Caroline Brandl, None; Horst Helbig, None; Maria A. Gamulescu, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2129. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Caroline Brandl, Horst Helbig, Maria A. Gamulescu; Choroidal Thickness Measurements During CSCR Treatment. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2129.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To determine changes in choroidal thickness in patients with Central Serous Chorioretinopathy (CSCR) during the first 3 months after initial diagnosis via Enhanced Depth Imaging Spectral-Domaine Optical Coherence Tomography (EDI-OCT).

Methods: : 10 patients with initial diagnosis of CSCR, who had received no treatment so far, participated in this prospective study. Routine opthalmological investigation was complemented by EDI-OCT. Choroidal thickness was measured both in affected and fellow eyes at the fovea, 500µm and 1000µm both temporal and nasal. EDI-OCT scans were furthermore performed through the leakagepoint (if present), visualised via fluorescein angiography. Follow-up measurements (eye-tracker controlled) were performed after 2-3 weeks, 6-8 weeks and 3 months. Statistical significance was determined via Students T-Test (p-value < 0.05).

Conclusions: : In patients with CSCR, average choroidal thickness not only demonstrated a significant thickening at baseline, but also showed a marked decrease after 3 months, however still not reaching normal levels. Additionally, choroidal thickening was also present in fellow eyes at baseline, but less prominent and only slightly decreased during follow up.

Clinical Trial: : Regensburg Ethical Committee, 10-101-0213

Keywords: choroid • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.